07.11.13
Dr. Deborah Dunsire has been named president and chief executive officer of EnVivo Pharmaceuticals and joins the company’s board of directors. Dr. Dunsire brings more than 25 years of scientific, clinical, operational and commercial experience in the pharma and biopharma industries.
Dr. Dunsire joins the company from Millennium, The Takeda Oncology Company, where she served as president and chief executive officer from 2005 to 2013. During that period, she led R&D, driving the development pipeline and increasing the commercialization of marketed products. Dr. Dunsire also served on Takeda’s board of directors. Prior to Millennium, she led the Novartis U.S. Oncology Business, playing a key role in the development and successful launch of several products. Dr. Dunsire is currently a board member of Allergan.
“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase III clinical trials in schizophrenia and will enter a Phase III clinical trial in Alzheimer’s disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.”
Dr. Dunsire joins the company from Millennium, The Takeda Oncology Company, where she served as president and chief executive officer from 2005 to 2013. During that period, she led R&D, driving the development pipeline and increasing the commercialization of marketed products. Dr. Dunsire also served on Takeda’s board of directors. Prior to Millennium, she led the Novartis U.S. Oncology Business, playing a key role in the development and successful launch of several products. Dr. Dunsire is currently a board member of Allergan.
“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase III clinical trials in schizophrenia and will enter a Phase III clinical trial in Alzheimer’s disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.”